ArticleESMO open2026

Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.

C-C Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.